Iván R. González, Medical Oncologist at Centro Oncológico Integral, shared on X:
“In the KRYSTAL-1 trial, the combination of Adagrasib plus Cetuximab shows efficacy and safety in metastatic colorectal cancer with KRAS G12C mutation. ORR was 34%, with a median duration of 5.8 months and overall survival of 15.9 months.
These data suggest a new standard of care and highlight the importance of KRAS G12C testing.”
Source: Iván R. González/X